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The relationships between cancer and stemness have a long history that is traced here. From the mid-19th century when the first
theory on the embryonic origin of cancer was formulated to works on embryonal carcinoma cells in the mid-20th century, many
steps have been crossed leading to the current cancer stem cell theory postulating that tumor growth is supported by a small
fraction of the tumoral cells that have stem-like properties. However, in the last fifteen years, many works regularly encourage us
to revise the concept of cancer stem cell.This article mentions key results that lead to a new perspective where cancer stem cells are
primarily seen as cells exhibiting increased epigenetic plasticity and increased gene expression variability.This perspective suggests
new therapeutical interventions consisting in stabilizing gene expression to control cancer cell proliferation and prevent stochastic
gene expression variations that could lead to therapeutic resistance.
1. Historical Roots
1.1. From the 19th Century to the Middle of the 20th Cen-
tury. It is possible to date the first mention of the role of
undifferentiated cells in cancer in the 1870s, with the debate
between Rudolf Virchow (1821-1902) and his student Julius
Cohnheim (1839-1884). Cohnheim extensively formulated in
1877 his theory of the embryonic origin of cancer, which
postulates that the origin of tumor development must be
attributed to the existence in the body of “embryonic rests”
that have remained unused during development [1]. This
idea was not revolutionary in itself because, as early as
1838, Johannes Mu¨ller (1801-1858) had described tumors as
the abnormal continuation of embryonic cell development
on the basis of morphological similarities. Virchow himself
had emphasized the correspondence between embryonic
and tumor development, indicating that these processes are
both derived from cell division and multiplication [1]. But
Cohnheim went further than the morphological similarities
by imagining a common origin of all tumors based on the
presence of persistent embryonic cells in the body. According
to him, if these cells receive the necessary blood supply,
they begin to proliferate uncontrollably because of their
embryonic nature. They subsequently form tumors that are
considered as a consequence of “errors” during development
[2]. Therefore tumors would be the result of the high
proliferation propensity of these embryonic rests. These rests
would also explain why various mature cell types can be
observed [1]. Finally Cohnheim additionally mentioned that
these embryonic cells can also be the origin of the normal cell
proliferation observed in physiological cases during puberty
or pregnancy [1].
Cohnheim’s theory was much discussed at the end of the
century and considered as a real alternative to the parasitic
or chemical theories of cancer. Experiments have tried to
demonstrate its validity, with limited success because the
reimplanted embryonic cells differentiated very often and
behaved normally. However, Max Askanazy (1865-1940) was
then able to obtain in rats tumors that resembled teratomas
(tumors that contain differentiated elements of all three
embryonic germ layers and that occur most commonly
as benign ovarian tumors, dermoid cysts, and, rarely, as
tumors of newborns) [2] the tumor type on which Cohnheim
based his generalization. Thus, teratomas became the pre-
ferred model for understanding the formation of all tumors
(although Virchow considered it an exception [1]), but also
for understanding normal cell proliferation phenomena in
adults. In 1907, Askanazy used the term stem cells (Stam-
mzellen) to designate these cells as embryonic remnants that
should be discarded in the early stages of development and
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whosematuration was delayed or stopped [2]. It is interesting
to note that Hugo Ribbert (1855-1920), professor of pathology
inBonn, formulated amodified version of Cohnheim’s theory
considering that sequestration of undifferentiated cells could
take place not only during development, but also during the
life of the individual because such cells could be generated
if a lack of “tissue tension” appears. It would trigger the
proliferation of these cells in their new environment [2]. On
the contrary, if cells are maintained in their normal physio-
logical context within a network of tissue interactions, their
proliferation capacity would be counteracted by this tension.
Finally, Theodor Boveri (1862-1915) was also interested in
cancer by observing that the abnormal distribution of chro-
mosomes during cell division causes the loss of proliferation-
inhibiting phenomena and leads to abnormal behavior of the
daughter cells that he has assimilated to the behavior of cancer
cells. Based on these observations, he formulated the first
chromosomal theory of cancer (see [3] for the genesis of the
first theories of cancer). From this perspective, he considered
that inmost cases the immature characteristics of cancer cells
are side effects of this abnormal distribution of chromosomes
and that embryonic rests can be incriminated only in rare
cases. These ideas had a great influence because tumor cells
have been considered during the following decades as well-
differentiated cells that have become dedifferentiated. This
was the opposite of Cohnheim’s conception. It was only in
the 1960s and 1970s that new works on teratocarcinomas
(malignant tumors that are more aggressive than teratomas
and formed of undifferentiated cells and differentiated cells
of all three embryonic germ layers) renewed in a different
modern context the question of the role of stem cells in the
genesis of cancers.
1.2. Study of Teratomas, Teratocarcinomas, and Embryonic
Carcinomas. As mentioned above, Julius Cohnheim based
his theory of the embryonic rest on the study of teratomas.
It is logically also that, based on teratomas, on the more
aggressive tumor type teratocarcinomas, and on the very
aggressive cancer embryonal carcinoma consisting only in
poorly differentiated embryonal carcinoma (EC) cells, efforts
were made to characterize the potential role of undifferen-
tiated cells in tumorigenesis [4, 5]. As early as 1953, a study
of one thousand cases of testicular tumors had concluded
that, in most cases, undifferentiated germinal cells are the
origin of tumor development because cells in these tumors
possess potentialities similar to those of the germinal cells
[6]. However, their exact nature remained to be identified.
In the same year, Leroy Stevens (1920-2015) began working
in Clarence C. Little’s (1888-1971) laboratory on the effect of
mutagenic and carcinogenic agents in variousmouse lines. By
systematically examining many mice, he found that the line
called “129” was particularly sensitive to testicular teratomas,
whereas this type of tumor had only been described in very
rare cases in mice. In 1954, Stevens and Little reported thirty
cases out of 3557 male “129” mice examined, about 1% [7].
In addition, these tumors were found to be transplantable
in series because the injection of tumor material under
the skin or into the abdominal cavity of new mice has
maintained tumor growth over sixteen generations. For the
authors, these tumorswere thus composed of rapidly dividing
undifferentiated cells of embryonic type [7].
Other subsequent studies on the “129” line showed that
these spontaneous tumors originate in the seminiferous tubes
[8], that the transplantation of teratomas into the mouse’s
abdomen forms “embryonic-like bodies” (or embryoid bod-
ies) [8, 9], and that, conversely, some embryonic tissues,
or even fertilized eggs, are capable of generating teratomas
and teratocarcinomas when they are implanted in the testis
of mice [10–12]. The second point has shown that these
tumors have more in common with the embryo development
than Stevens originally thought because the embryoid bodies
have an organization in endoderm and ectoderm similar to
the one of the embryo [13]. But the last point is essential
because, contrary to the initial hypothesis that these tumors
develop from poorly differentiated germ cells, it showed that
highly undifferentiated cells of the early embryo, and not just
primordial germ cells, are capable of generating teratomas.
Stevens referred to this type of cell as a “pluripotent embry-
onic stem cell” (the origin of the term embryonic stem (ES)
cell [1]), a term that was long interchangeable with that of EC
cells [1, 2].
G. Barry Pierce (1925-2015) at the University of Michigan
was more interested in embryonal teratocarcinomas and
carcinomas in the early 1960s and showed in 1964 that EC
cells (derived from these two types of cancer) produce var-
ious differentiated tissues and embryonal carcinomas when
transplanted in mice [14]. He interpreted this observation
as supporting the theory of cancer stem cells (CSC) and
showed at the same time that EC cells were multipotent [14].
These cells can be maintained in an undifferentiated state ex
vivo or by transplantation in the animal, while maintaining
a set of chromosomes that appears normal [4, 13]. But they
can also be intentionally differentiated ex vivo, and their
resemblance to the normal embryonic cells contained in the
internal mass of late blastocysts led to studies showing that
EC cells, when injected into early embryos (at the blastocyst
stage), are able to contribute to the normal development
of “chimeric” animals [15–17]. Finally, it is remarkable that
Pierce, from the end of the 1960s, relied on these results to
formulate a theory of cancer where tumors would be formed
by “induction” of nongenetic origin or by disruption of the
“developmental field”, rather than by mutation in a single
cell which would then multiply anarchically [18]. This would
make it a reversible phenomenon. This conception needs
more than ever to be reconsidered as a real alternative to
the theory of somatic mutations [3] (see below). Thus, the
1960s brought the modern era of stem cell research through
a curious mix of studies on physiological and pathological
phenomena that intertwined and nourished each other.
1.3. From Murine EC Cells to Human ES Cells. In the late
1960s and the 1970s, several groups were able to establish
the first murine EC cell lines and pave the way for their
molecular characterization [4]. Then it was in the early
1980s that human lines of such cells were obtained. From
the beginning, the isolation and characterization of EC cell
lineages depended on specific molecular markers that must
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be identifiable in living cells [4]. The first marker used was
the expression of the enzyme called alkaline phosphatase,
which is strongly expressed in EC cells [5]. But it was the
development of monoclonal antibodies in the 1970s that led
to the development of molecular detection of these cells. For
example, the Forssman and SSEA1 (stage-specific embryonic
antigen 1) antigens are specific for murine EC cells, with the
latter not reacting with those of human origin [5]. On the
other hand, two other antigens, SSEA3 and SSEA4, have been
found to be specific for human EC cells [5]. In the absence of
direct studies on human embryonic cells because of the lack
of an established lineage, it was supposed that the results on
human EC cells could be extrapolated to what happens in the
early embryo. But the fact that human and murine EC cells
do not have the same characteristics made this extrapolation
uncertain [4].
EC cells can be obtained from mouse embryos, but
indirectly after transplantation of embryo tissues into an
ectopic location, then development of a teratocarcinoma,
and finally isolation of EC cells from this teratocarcinoma.
The next obvious step was to obtain similar cells directly
derived from embryos, i.e., true murine ES cells [5]. The
first mouse ES cell lines were independently isolated by two
research groups from ex vivo-grown blastocysts [19, 20].
This was a decisive step as they were isolated without the
production of teratocarcinomas. These mammalian ES cells
were isolated from the internal mass before separation of
the epiblast and the primitive endoderm. But the precise
correspondence between the ES cells obtained and grown
in vitro, and their equivalent in the embryo have long
been controversial. It now appears that ES cells are more
similar to epiblast cells than to cells in the early internal
mass and that pluripotency is acquired during epiblastic
type formation [21]. Nevertheless, studies have confirmed the
similarity between ES and EC cells, in terms of molecular
markers and ability to differentiate ex vivo and in vivo [5].
Moreover, in addition to their embryonic features, ES cells
are tumorigenic and form teratocarcinomas when injected
into an adult organism. Since these teratocarcinomas are
indistinguishable from those generated by EC cells, this was
also considered as an important criterion for the embryonic
nature of ES cells [13].
Works on murine ES cells were initially used rather to
create protocols of production of transgenic mice, thanks to
the introduction of precise mutations into their genome ex
vivo in order to study their effects in animals, than to study
the biology of these cells and ex vivo differentiation processes
[4, 13]. Gene inactivation in these cells by the introduction
of a nonfunctional copy has been a key issue in the 1980s
[13] and a major step was crossed when it was possible to
effectively select ES cells in which these rare events occurred
[22, 23].Other mammalian ES cell lines were obtained during
the 1980s, but primate ES cells were cultured only in 1995 [24].
Finally, the production of the first lines of human ES cells
arrived in 1998 thanks to two groups that independently iso-
lated them from aborted embryos [25] or embryos fertilized
in vitro [26]. These works may seem late when considering
the availability of markers necessary for the identification of
human ES and EC cells, and of ES cell isolation techniques
that have been established for a long time for mice and are
comparable for human cells. This delay can be explained
by difficulties in obtaining human embryos allowing this
isolation and especially by the reluctance of many researchers
on works that cause problems of legal nature, and political
and moral dilemmas.
1.4. Reemergence of the Cancer Stem Cell Concept: Molecular
and Cellular Aspects. Another phenomenon has greatly con-
tributed to the need of molecular characterization of stem
cells: the reemergence of the concept of CSC and its role in
carcinogenesis [27]. Differentiation problems in tumors were
somewhat neglected in the 1980s in favor of the effects of
oncogenes on proliferation and genome stability. This was
still the case in the early 1990s, especially because many
researchers have considered teratocarcinomas, which served
as a model for studying these problems of differentiation,
as a particular case of no great interest for the study of
other cancers. It is the study of certain forms of leukemia, in
particular acute myelogenous leukemia (AML), that put the
concept of CSC at the forefront [27].
As such, the studies of John E. Dick’s lab and colleagues
published in 1994 and 1997 were crucial as they demonstrated
that only few rare cells ofmouseAML are capable of initiating
this leukemia in other mice. Moreover, they showed by series
of successive transplants that these cells have a very high
capacity for self-renewal, which is an essential characteristic
of stem cells [28, 29]. The tumors that appear after trans-
plantation are composed of a mixture of tumorigenic cells
and nontumorigenic cells similar to the one of the initial
tumor [29]. This shows that the same process is reproduced
at each cancer development: CSC produce both cells identical
to those that were transplanted (by self-renewal) and more
differentiated cells that lose their tumorigenic potential by
a process of differentiation. These CSC have now been
identified in many types of cancers, including solid tissues
[30]. Indeed, the presence of CSC in solid tumors was
demonstrated in the 2000s first in breast cancers where as
few as hundred CSC were able to form tumors in mice,
whereas tens of thousands of cells with alternate phenotypes
failed to form tumors [31]. Then works on brain and colon
cancers further identified such subpopulations of rare cells
that produce tumors in vivo [32, 33].
In many ways, the CSC identified in AML were close to
normal blood stem cells. This enhanced the interest in trying
to characterize their molecular features. But this interest was
also based on the desire to find what distinguishes CSC from
normal stem cells and what would allow targeting them for
therapy without affecting normal cells. Conversely, this has
also contributed to better characterizing of normal stem cells
[34].
At the same time, the CSC hypothesis was refined. It
now postulates that tumors are hierarchically organized, just
like normal tissues. They would be maintained by a fraction
of cells responsible for tumor formation and growth. These
cells (also known as “cancer-initiating cells” or “cancer stem-
like cells”) possess key characteristics of normal stem cells,
namely, self-renewal, unlimited proliferation but infrequent
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divisions, and an ability to produce offspring capable of differ-
entiation. However, these CSC would generate cells that only
partially differentiate and whose differentiation appears to be
stopped at intermediate stages. Here again, this blockage has
contributed to further study of the differentiation of normal
stem cells. As with normal stem cells, the niche concept has
also been applied to CSC. This would be a specific environ-
ment necessary for the survival and maintenance of their
properties [35]. Finally, many factors have led researchers
interested in stem cells to characterize the signaling pathways
that maintain stemness, the surface markers that allow their
isolation, or the networks of transcription factors that form
and generate their phenotypic identity. But this view of the
stem cell based on a specific and fixed identity soon proved
to be insufficient, or even largely false.The 2010s have indeed
changed our conception of stemness. These changes have
a fundamental impact on the conception of differentiation
processes, but must also be considered in oncogenesis.
2. A new Perspective on Cancer Stem Cells
2.1. Stem Cells: State rather than Entity. ES cells possess an
unusual nuclear structurewhereDNAappears to be packaged
in a more open chromatin structure than in differentiated
cells. In the mid-2000s, this was associated with the fact that
chromatin proteins are more rapidly exchanged at the DNA
level, reflecting their weaker interactions [36]. In addition,
ES cells show an enrichment in epigenetic marks associated
with high gene expression activity and possess fewer of those
that make chromatin too compacted to allow expression [37].
It remained to analyze the real impact of this particular
chromatin structure on gene expression.
Tom Misteli’s team published in 2008 an essential work
that deeply contributed to the change of our vision of stem-
ness [38]. It showed that mouse ES cells express their genes in
a generalized andwidespreadmanner and that differentiation
is associated with large-scale repression of gene expression at
the genomic level. Gene expression profiles clearly become
more discontinuous in differentiated cells. The “hyperactiv-
ity” of ES cells in terms of gene expression is accompanied
by the presence in unusually high levels of proteins involved
in chromatin remodeling and gene transcription. Moreover
almost all of the tissue-specific and differentiation genes that
have been examined are sporadically expressed at a low level.
Thus eleven out of twelve genes associated with terminal dif-
ferentiation and therefore not expected in ES cells have been
found to be expressed at 0.25 to 20 RNA copies per cell, sug-
gesting a strong stochastic appearance of this expression [38].
Stochasticity in gene expression was previously demon-
strated in the early 2000s in microbial populations thanks
to the development of single cell analysis by flux cytometry
and to the construction of synthetic gene networks that led
to the discovery of large fluctuations in gene expression levels
among individual cells in isogenic populations [39, 40]. The
term noise in gene expression is now used to designate this
variation in the expression level of a gene under constant
environmental conditions [41]. It is also used to quantify the
heterogeneity in expression from cell to cell by dividing the
variance across the population by the mean [42].
It should be noted that this generalized transcriptional
activity had already been observed in hematopoietic stem
cellswhere the expression of differentiation geneswas noticed
before any differentiation, with a large portion of the genome
expressed in the undifferentiated state [43]. However this
new study on ES cells has had a strong impact and must
be associated with the work from Sui Huang’s laboratory
published also in 2008. It focused on progenitor cells of the
hematopoietic system [44]. Two major observations were
made. On the one hand, these cells very heterogeneously
express the stem cell-associated Sca-1 gene, and when a
small homogeneous fraction of this population is isolated
and cultured again, it spontaneously returns to the origi-
nal heterogeneity after few days. On the other hand, the
expression or absence of expression is related to a propensity
to differentiate towards one pathway or the other in the
hematopoietic system. This reflects an important bias related
to this expression. Then many other articles have confirmed
and reinforced these first results and brought interesting
results. In particular, gene expression variability in ES cells
in vitro depends on the culture conditions and therefore on
the cellular environment [45].
Thus stem cells cannot be defined by a stable phenotype.
They are in a state of permanent instability and are not
defined by the stable expression of few specific genes. Some
transcription factors considered to be specific to ES cells, such
as the pluripotency-involved Nanog protein [46] or various
other “markers” [47], are expressed with high heterogeneity.
They seem to fluctuate between high and low levels of
expression, even if a clustering into more or less activated
subgroups is possible [48]. A detailed study of the behavior of
the Nanog protein has led to the conclusion that its variations
are an essential element of the pluripotent state [49]: cells
randomly fluctuate between a stable state of high Nanog
expression and another state with low Nanog expression
which is highly unstable, giving rise to heterogeneous cell
populations. Noise-driven fluctuations can lead individual
cells to stochastic excursions into this transient state with low
levels of Nanog where they are more likely to differentiate
depending on the culture medium [49]. Thus pluripotency
seems dependent on the stochastic expression fluctuations of
a panel of genes, and the role of the gene regulatory network
centered on Nanog could be to generate this heterogeneity
[49]. Similarly, mouse ES cells that express less Nanog have
a stronger tendency to differentiate, and cells with higher
Nanog levels have a more stable gene expression pattern
under various culture conditions and minimal expression of
differentiation genes [50]. Nevertheless, other studies suggest
that differences in the expression of Oct4, Nanog, or c-Myc
proteins in mouse ES cells poorly affect pluripotency [51, 52],
although, again, the propensity to differentiate depends on
their level of expression [49, 52].
As mentioned below, there is a generalized and highly
stochastic gene expression, including that for differentiation
genes, in ES cells, and the observed heterogeneity is recon-
stituted from a homogeneous subpopulation that would have
been isolated. But these heterogeneous subpopulations have
varying inclinations for various differentiation pathways.
These works are contradictory to what was postulated in the
Journal of Oncology 5
model that prevailed in the early 2000s when the finely regu-
lated stem cell was supposed to express only few specific genes
in a homogeneous manner, reacting also in a homogeneous
way to differentiation “signals”. Very few researchers had
a different conception. Dov Zipori, who based his analysis
mainly on hematopoietic cells, had suggested in 2004 that it
actually seems impossible to define a molecular signature of
stem cells and that generalized and variable gene expression
defines these cells [53]. Moreover, proteins associated with
differentiated cell types are expressed with high heterogeneity
in vivo in early mice embryos [54], and differentiation
would thus have be considered as the suppression of this
generalized and variable gene expression [55]. Also, this has
to be correlated with the transition from a very open and
dynamic chromatin to amore stable and closed state [56].The
expression level of the vast majority of genes indeed decreases
during differentiation [55].
An intriguing hypothesis explaining the heterogeneity
and the epigenetic instability of stem cells is related to energy
metabolism. Indeed, a whole set of experiments indicates
many connections between pluripotency and their metabolic
activity [57, 58]. For example, stimulation of glycolysis by
chemical agents [59] or cell culture under oxygen-poor
conditions [60] allows dedifferentiation of differentiated cells
into pluripotent cells. Inhibition of glycolysis or stimulation
of oxidative phosphorylation has the opposite effect [59, 61].
This is consistent with the fact that ES cells differentiation is
associated with a metabolic switch from a glycolytic type to
an oxidative type [62].
The link between the highly dynamic chromatin status in
pluripotent cells andmetabolism comes from the observation
that the latter producesmolecules that are used for chromatin
modification reactions. Actually metabolism emerges as a
key player in epigenetics, with metabolites such as acetyl-
coA, S-adenosylmethionine, or𝛼-ketoglutarate among others
that are cofactors used by chromatin modifiers [63, 64].
The cellular amount of these key metabolites, which reflects
the metabolic state of the cell, clearly affects the chromatin
state with direct consequences on the expressed portion of
the genome. Thus, fluctuations in their concentration as a
function of the metabolic activity would directly result in
global changes in chromatin opening and thus in changes in
the level of expression variability [65]. Ametabolism favoring
the production of molecules such as acetyl-coA used in
reactions that open up chromatin (histone acetylation) would
allow a more generalized and stochastic gene expression.
Finally, it was proposed in 2013 to be applied to pluripo-
tency statistical methods used in thermodynamics [66].
Indeed, the permissive chromatin state in stem cells means
that stemness cannot be well-defined at the single cell
level. Functional pluripotency spontaneously emerges from
dynamic variability intrinsically linked to the pluripotent
state. This variability would be spatiotemporally regulated
during in vivo development, but these restrictions would be
largely absent in vitro and the intrinsic variability of the
population would become apparent. From this perspective,
the highly variable panel of gene expression in stem cells
is expected to allow many developmental choices. On the
contrary, the appearance of constraints during differentiation
(see below) makes it possible to obtain less various and better
defined expression panels so that the differentiated state is
characterized by stable phenotypes. This process is linked to
the progressive closing of the chromatin.
2.2. Cancer Stem Cells: A Controversial Theory. The current
CSC theory postulates that a small proportion of tumor cells
are able to support their growth because they provide dividing
daughter cells whose differentiation is incomplete, which
proliferate rapidly (unlike CSC) and which have a limited
number of possible divisions and form the majority of the
tumor. In fact, these daughter cells do not self-renew and are
unable to form new tumors in healthy animals, whereas these
two points are the functional definition criteria for CSC.
This concept of CSC allowed, on the one hand, better
understanding and explaining the heterogeneity of cells
within tumors. Indeed, poorly differentiated cells such as
CSC seem better able to generate very heterogeneous cell
populations by uncontrolled differentiation phenomena than
differentiated cells that dedifferentiate. This phenomena is
especially evident when looking at the modification of the
balance between symmetric and asymmetric divisions of
CSC during cancer progression. Early stage tumors are
characterized by asymmetric division of CSC to form well-
differentiated tumors composed of a mix of differentiated
states, while late-stage cancer suppresses asymmetric divi-
sion, which promotes symmetric self-renewal to form undif-
ferentiated tumors [67, 68]. On the other hand, the concept
of CSC allows considering otherwise the emergence of ther-
apeutic resistance. CSC are more likely to escape chemo- or
radiotherapeutic treatment and can transmit this resistance
to their offspring. Recurrent cancers from these CSC are
therefore more resistant to treatment than primary tumors.
This phenomenon has already been observed in many can-
cers like breast cancers where, following chemotherapeutic
treatment, secondary tumors showed a significant increase in
the proportion of CSC since only the other cells were killed
by chemotherapy [69]. CSC would therefore be responsible
for the recurrence of the tumor, after a period of apparent
remission [70].The same phenomenon has also been demon-
strated in glioblastomas, for instance, [71]. Finally, in addition
to tumor recurrence, CSC are also suspected to be key drivers
in metastatic dissemination [72].
Other studies have also reinforced the CSC theory. Those
mentioned so far have revealed that only a subpopulation of
cancer cells is able to form new tumors in immunodeficient
animals, but none had shown the role of CSC in the devel-
opment of solid endogenous tumors until 2012.Three studies
on brain [71], intestinal [73], and skin [74] tumors used in
vivo cell line tracing techniques to demonstrate the existence
of CSC, concluding that it is necessary to target and eliminate
CSC to eradicate cancer. But this is a real challenge because of
the low proliferation of these cells (chemo- and radiotherapy
most often affect cells that actively proliferate).
Another major issue in this field is the cell of origin
in cancers: is cancer caused by a normal stem cell or a
differentiated cell that is dedifferentiated? The hypothesis of
normal stem cells was reinforced by a study describing the
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mathematical correlation between the frequency of appear-
ance of cancers in some tissues and the frequency of cell
division at the basis of the renewal of these tissues, and
therefore the frequency of mutations that appear over the
divisions in these cells [75]. However, both hypotheses seem
possible [76, 77], even if mutations in known oncogenes have
only a very limited impact on the expansion of stem cells
that are in their niche [78]. Indeed, on the one hand, these
common mutations confer only a very limited competitive
advantage and the mutated cells are easily and stochastically
replaced by “normal” equivalents from neighboring cells. On
the other hand, mutations within osteoblastic cells which
constitute, among other cells, the niche of hematopoietic stem
cells, are sufficient to generate leukemia [79, 80]. It seems
that it is the interactions of the stem cells with their niche,
rather than their genetic content, that matters for cancerous
development.
Beyond their origin, the question of their proportion in
the tumor and their characteristics raises acute problems
in the current framework. This was highlighted in 2008 by
a study which, while it was thought that CSC constituted
0.0001% to 0.1% of the tumor mass, identified up to 25% of
CSCwhenmelanoma cells were transplanted into immunod-
eficient mice [81]. In addition, no specific molecular marker
was identified to differentiate them from other tumor cells.
This major difference in CSC frequency would be related
to the environment in which cells try to proliferate because
the same authors showed that a protocol identical to the
one used in a previous study gave the same low frequency
of tumorigenic cells (0.0001%) [82]. On the other hand,
this proportion is increased by various modifications of the
original protocol (lengthening of the period of observation,
injection with an environment rich in components of the
extracellular matrix to increase cell viability, or host more
immunodeficient). The CSC frequency therefore depends
on the method used [81] and cell-cell interactions seem to
play a crucial role. It is clear that this greatly complicates
the CSC theory [83] or even puts it in difficulty. Cells that
are apparently nontumorigenic can become tumorigenic in
the presence of the appropriate microenvironment. Thus,
being too rigid in the way of defining CSC is not realistic
[83].
In addition, at least some markers used to identify CSC
are not stable. For instance, within human melanoma cells,
only one subpopulation expresses the JARID1B enzyme [84]
and, compared to melanoma cells that do not express it, this
subpopulation does not proliferate much, which seems to
make it fall into the category of CSC. But intriguingly, the
expression of the JARID1B enzyme, which seems to be a CSC
marker, is dynamic: its expression can frequently appear in
cells that did not express it initially. The stem state could
therefore be acquired by any cell at any time, rendering
difficult any therapeutic intervention targeting CSC [85].
This plasticity of the CSC state has also been recently
demonstrated in glioblastoma [86]. Conversely, glioblastoma
CSC can express various differentiation markers and still
contribute to tumor initiation and self-renewal [87]. This
has led some researchers to propose a stochastic model of
CSC where each cell of a tumor has the ability to act as
CSC [27, 88]. Variations in this ability are due to intrinsic
variations in the cells and to the environment in which these
cells are located. (In the classical hierarchical model, when a
cell leaves the stem state, the phenomenon is irreversible and
none of its descendants can restore it.)
The latest versions of the CSC theory evoke a “tumor
reprogramming” due to genetic alterations initiating cancer
that would “reset” the epigenetic status and gene expres-
sion in initially healthy cells [89]. Thus, oncogenes would
contribute less to the development of cancers by inducing
cell proliferation than by causing “developmental reprogram-
ming” of the epigenome of the affected cell [90]. This would
allow these cells to aberrantly and pathologically differentiate.
The parallelism with the cell reprogramming process which
aims at producing induced pluripotent stem cells (iPS cells)
is therefore striking. In addition, the initial genetic events
that would have the main role of causing this reprogramming
would become, like in iPS cell generation, useless for tumor
progression when reprogramming is complete. This would
explain why these alterations are no longer maintained
or commonly observed [91]. However, the origin of early
dedifferentiation in cancer may be considered otherwise
by focusing on the tissue level [92–94] (see below). This
would resolve many paradoxes concerning, for example, the
widespread presence of so-called oncogenic alterations (that
is to say, supposed to cause cancer) in healthy tissues, such as
in the skin [95] or in the oesophagus [96].
Finally, metabolism has emerged as a key player in gene
expression and epigenetics also in cancer cells [97]. More
specifically, some reports showed that CSC preferentially
use glycolysis while other works reported a propensity for
mitochondrial oxidative phosphorylation suggesting a pos-
sible metabolic plasticity [98, 99]. In any case, it is entirely
possible that the epigenetic plasticity that characterizes can-
cer cells and drives tumor adaptation [100] occurs mainly
through metabolic modifications in CSC that directly impact
epigenetics. Their specific metabolic state probably makes
them very plastic in terms of gene expression with a more
widespread and stochastic expression of the genome as in ES
cells.
2.3. Cancer Stem Cells as Cells with Destabilized Gene Expres-
sion. As discussed above, gene expression variability (noise)
is a source of cellular heterogeneity and phenotypic plasticity
that are both hallmarks of embryonic and adult stem cells
[101]. Variation in gene expression and the associated phe-
notypic heterogeneity account for randomness in cell fate
decisions in stem and progenitor cells [44]. Moreover the
degree of gene expression variability is modulated during
development and differentiation: following a phase of highly
widespread and variable gene expression, cells progres-
sively transit towards more homogeneous, coordinated, and
restricted gene expression profiles [38, 102, 103] associated
with amore restrictive chromatin [104].When hematopoietic
stem or progenitors cells are induced to differentiate in
vitro, a transient state characterized by an increased in gene
expression variability is observed [102, 103] before its strong
decrease.
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Cellular interactions seem to be the major determinants
in constraining and decreasing this expression variability and
possess all the requirements to be considered as the main
“constraints” leading to stable differentiated states. Various
works on Drosophila or Caenorhabditis elegans embryos
suggest that cellular communications and strong signaling
are essential in stabilizing and homogenizing gene expression
during cell differentiation [105, 106]. In mouse blastocysts,
an initial phase of stochastic expression of individual genes
precedes signal reinforcement through Fgf4 that segregates
early lineages [107]. Also, direct cell contacts through gap
junctions spatially coordinate prolactin gene expression in
pituitary adult tissue [108], and disruption of gap junctions by
enzymatic digestion or pharmacological inhibition reduced
transcriptional coordination between cells [108], showing
that perturbation of cell communication can enhance gene
expression variability and phenotypic heterogeneity among
differentiated cells. Thus, an alternative model of cancer
where disruption of cellular interactions is the initial event by
producing phenotypic plasticity and less differentiated cancer
cells can be proposed [3, 92–94]. Basically, this tissue dis-
ruption would produce cells exhibiting increased epigenetic
plasticity and increased gene expression variability. Thus CSC
should be primarily defined as cells with such destabilized
gene expression because they are no more in the normal
cell-cell interaction network that stabilizes phenotypes and
differentiation features in healthy tissues [3, 92–94].
This hypothesis has therapeutical implications. Indeed, if
cancer cells remain intrinsically unstable and plastic because
they do not normally interact with their native microen-
vironment, targeting driver genetic events is clearly not
sufficient because this phenotypic instability and plasticity
would allow them to counteract these treatments [93, 109].
On the contrary, molecules that stabilize gene expression
and thus help to restore full differentiation and quiescence
would be more prone to control cancer cell proliferation.
As previously proposed as a general framework [109] and
then specifically for multiple myeloma [94], only molecules
able to interact with cancer cells and mimic their original
microenvironment would be able to stabilize them. It should
consist in pharmacological intervention with peptides or
small molecules that mimic interacting domains of proteins
that are part of the cell-cell interaction network in the healthy
tissue. Nevertheless, as also previously suggested, this would
not be sufficient. The reexpression through epigenetic drugs,
for instance, of genes coding for proteins allowing these
interactions would be an obligatory first step before introduc-
ing agents mimicking the native microenvironment. Indeed
the subsequent stabilization of this reexpression would be
achieved by bringing in their environment molecules that can
interact with them [3, 109]. While there is no experimental
evidence of the relevance of such a two-step pharmacological
intervention, it could be speculated that it would improve the
efficiency of epigenetic drugs that currently miss the second
crucial step. A real differentiation therapy should consist in
stabilizing the expression of the reexpressed proteins involved
in differentiation and cell-cell interactions [109].
The role of gene expression variability in the appearance
of therapeutic resistance independently of genetic variations
is now demonstrated [110, 111]. Thus targeting this funda-
mental property of cancer cells, and especially of CSC, seems
to be of major importance. Their plasticity in terms of gene
expression and their ability to easily produce gene expression
outliers with extreme expression levels and/or a large range
of gene expression profiles have to be the privileged targets in
anticancer therapy. And only concepts coming from recent
developments in stem cell biology would help to define such
therapeutic strategies.
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